Collaborative Consortia Studying ALS Biomarkers

Target ALS is soliciting proposals from multidisciplinary groups focused on the discovery and development of novel fluid or tissue-based biomarkers of disease progression and stratification using novel, innovative, and complementary approaches including applications of AI and machine learning (ML).

Target ALS is particularly interested in supporting projects that propose the study of:

• novel biomarkers predictive of disease progression or phenoconversion 
• biomarkers with utility as treatment response 
• biomarkers for patient population stratification (e.g., fast vs slow progressors, cognitive impairment, peripheral immunity)
• novel analytical approaches to blood-based biomarkers, including AI/ML-extracted signatures

Funding: $130,000 per lab per year (max. budget per year is $500,000)

Duration: 2 years

Research Authority due date: 12.5.26

LOI (required) due date: 19.5.26

Full proposal due date: 20.7.26